Synthetic hGRF analogue

Tesamorelin

Also catalogued as TH9507, TH-9507.

CAS number: 218949-48-5
Molecular formula: C221H366N72O67S
Molecular weight: 5135.9 g/mol
PubChem CID: —

Identity

CAS number: 218949-48-5
Molecular formula: C221H366N72O67S
Molecular weight: 5135.9 g/mol
Residues: 44

The full 44-residue human growth-hormone-releasing factor sequence with a trans-3-hexenoyl group on the N-terminal tyrosine.

What it is

Tesamorelin (developed under the code TH9507) is a synthetic analogue of human growth-hormone-releasing factor, hGRF(1–44), in which a trans-3-hexenoyl group is attached to the tyrosine at the amino terminus. The peptide backbone is otherwise the native 44-residue sequence.

The N-terminal modification makes the molecule resistant to cleavage by dipeptidyl aminopeptidase IV, slowing its degradation in plasma relative to the native sequence, as described in the non-clinical characterisation published in 2007. The compound was developed by Theratechnologies.

Regulatory status

Tesamorelin is the active ingredient of a prescription product approved by the U.S. FDA in 2010 (Egrifta). The research material listed here is not that product and is not a drug.

Primary literature

Ferdinandi ES, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology 2007.
doi:10.1111/j.1742-7843.2007.00008.x

Citation titles are reproduced verbatim from the journal record. A citation documents the molecule's published identity and history; it is not a claim about the material sold here.

Loading…

What it is

Primary literature

Citation titles are reproduced verbatim from the journal record. A citation documents the molecule's published identity and history; it is not a claim about the material sold here.